Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for migraine sufferers: drug works when others fail

NCT ID NCT06701526

Symptom relief Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests whether eptinezumab can reduce migraine days and improve quality of life in 164 adults who previously did not get enough relief from other CGRP-targeting migraine drugs. Participants receive the drug and report changes in migraine frequency and severity over time. The goal is to see if this treatment works for people who have not responded well to similar therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

164 people

The number who actually took part.

Started

Dec 2024

Finished

Sep 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * The participant has a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders 3rd Edition (ICHD-3) guidelines with a history of migraine of at least 12 months prior to the Screening Visit. * The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit. * The participant has documented evidence of recent inadequate response to either one anti-CGRP monoclonal antibody (mAb) (other than eptinezumab) or one gepant, indicated and used for migraine prevention. Key Exclusion Criteria: * The participant has taken more than 10 tablets of ubrogepant or more than 8 tablets of rimegepant per month as an acute migraine medication in the 1 month prior to the screening visit and during the 4-week baseline period. * The participant has previously had an inadequate response to more than one CGRP-targeting therapy (anti-CGRP mAb or gepants), indicated for migraine prevention. * The participant has a history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for \>5 years prior to the first dose of eptinezumab. Male participants with abnormal prostate-specific antigen levels according to national/local guideline may be enrolled in the trial provided they have been followed up, have been asymptomatic, and have had no treatment for prostate cancer. Participants under surveillance for a low and stable level of M-component are allowed. * The participant has previously been treated with eptinezumab. Other protocol-defined inclusion and exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • Albany Medical College

    Albany, New York, 12208-3412, United States

  • Baptist Health Center for Clinical Research (BHCCR)

    Little Rock, Arkansas, 72205-6355, United States

  • Brainstorm Research, Inc.

    Miami, Florida, 33176, United States

  • C7 Research

    Cleveland, Ohio, 44109, United States

  • Chicago Headache Center and Research Institute - Chicago

    Chicago, Illinois, 60657-9269, United States

  • Crescent City Headache and Neurology Center

    Chalmette, Louisiana, 70043-1668, United States

  • Dent Neurosciences Research Center

    Amherst, New York, 14226-1727, United States

  • Hasbani Neurology - New Haven

    New Haven, Connecticut, 06511, United States

  • Headache Wellness Center

    Greensboro, North Carolina, 27405-6962, United States

  • KCA Neurology, PLLC

    Franklin, Tennessee, 37067, United States

  • Mass Institute of Clinical Research

    Westborough, Massachusetts, 01581, United States

  • Mayo Clinic - Vascular Center - Arizona

    Phoenix, Arizona, 85054-4502, United States

  • Michigan Headache & Neurological Institute (MHNI)

    Ann Arbor, Michigan, 48104-5131, United States

  • Neurology Center of New England, PC

    Foxborough, Massachusetts, 02035, United States

  • New England Institute for Neurology and Headache (NEINH) - Stamford

    Stamford, Connecticut, 06905, United States

  • North Suffolk Neurology - Port Jefferson Station

    Port Jefferson Station, New York, 11776, United States

  • Preferred Primary Care Physicians - Pleasant Hills - Curry Hollow Road

    Pittsburgh, Pennsylvania, 15236-4604, United States

  • St. Joseph's Hospital and Medical Center-Barrow Neurological Institute - Barrow Brain Tumor Resea...

    Phoenix, Arizona, 85013-4409, United States

  • Sunwise Clinical Research, LLC

    Walnut Creek, California, 94549-4500, United States

  • The Neuron Clinic - Escondido

    San Marcos, California, 92069, United States

  • Thomas Jefferson University Hospital - Breast Care Center

    Philadelphia, Pennsylvania, 19107-5563, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.